Form 4: Avidity Biosciences CEO Sells Shares Under 10b5-1 Plan

Avidity Biosciences President and CEO, Sarah Boyce, exercised stock options and sold 50,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Sarah Boyce, President and CEO, and a Director of Avidity Biosciences, Inc., reported transactions involving the company's common stock.
• On September 5, 2025, Boyce exercised options to acquire 50,000 shares of common stock at an exercise price of $1.24 per share.
• Concurrently, on September 5, 2025, she sold 50,000 shares of common stock at a weighted-average price of $49.9487 per share. The sales occurred in multiple transactions ranging from $49.76 to $50.12.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024.
• Following these transactions, Boyce directly owns 305,871 shares of common stock and 1,022,015 stock options.

Sentiment

Score: 5

Explanation: The transaction is neutral as it represents a pre-planned liquidity event by a key executive under a Rule 10b5-1 plan, rather than a reaction to new company performance or strategic shifts. While it involves insider selling, the pre-scheduled nature mitigates negative interpretations.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates a planned liquidity event rather than a reaction to recent non-public information.
• The exercise of options and subsequent sale allowed the CEO to realize significant value from previously granted equity awards, demonstrating the value creation for long-term equity holders.
• The option award exercised was fully vested and exercisable, reflecting the achievement of prior performance or tenure milestones.

Negatives

• The sale of 50,000 shares by a key executive, even if pre-planned, could be perceived by some investors as a reduction in direct ownership and potentially a signal of reduced conviction, although the 10b5-1 plan mitigates this.
• A reduction in direct common stock holdings from 355,871 to 305,871 shares (after accounting for the exercised options that were immediately sold).

Risks

• Potential negative market perception of insider selling, despite the transaction being pre-planned under a Rule 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The option exercise and sales reported were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024, by the Reporting Person.

Industry Context

This filing reports an individual insider transaction and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may observe a reduction in direct common stock ownership by the CEO, which could lead to varied interpretations, though the 10b5-1 plan typically alleviates concerns about opportunistic selling.

Key Dates

Recommendation

The reported Form 4 details a pre-scheduled exercise of options and sale of shares by the CEO, Sarah Boyce, under a Rule 10b5-1 plan. This type of transaction is typically a planned liquidity event for an executive and does not inherently signal a change in the company's fundamental outlook or performance. While insider selling can sometimes be viewed negatively, the existence of a 10b5-1 plan adopted well in advance (August 15, 2024) suggests it is not based on recent, undisclosed material information. Therefore, without additional information regarding the company's operational performance, strategic direction, or broader market conditions, this filing alone does not provide a basis for a 'buy' or 'sell' recommendation. Investors should 'hold' and consider this transaction as a routine executive compensation and liquidity event.

Keywords

Avidity Biosciences, RNA, Sarah Boyce, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Biotechnology, CEO Transaction